Creative Medical Technology (NASDAQ:CELZ – Get Free Report) and Niagen Bioscience (NASDAQ:NAGE – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.
Analyst Ratings
This is a breakdown of current recommendations for Creative Medical Technology and Niagen Bioscience, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Creative Medical Technology | 0 | 0 | 0 | 0 | 0.00 |
Niagen Bioscience | 0 | 0 | 5 | 0 | 3.00 |
Niagen Bioscience has a consensus target price of $13.22, indicating a potential upside of 35.87%. Given Niagen Bioscience’s stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than Creative Medical Technology.
Valuation & Earnings
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Creative Medical Technology | $14,000.00 | 615.10 | -$5.49 million | ($3.18) | -1.05 |
Niagen Bioscience | $116.30 million | 6.67 | $8.55 million | $0.21 | 46.33 |
Niagen Bioscience has higher revenue and earnings than Creative Medical Technology. Creative Medical Technology is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Creative Medical Technology has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500.
Profitability
This table compares Creative Medical Technology and Niagen Bioscience’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Creative Medical Technology | N/A | -85.26% | -81.49% |
Niagen Bioscience | 15.24% | 23.12% | 15.53% |
Insider and Institutional Ownership
1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 2.8% of Creative Medical Technology shares are held by insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Niagen Bioscience beats Creative Medical Technology on 13 of the 14 factors compared between the two stocks.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
About Niagen Bioscience
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.